Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Retatrutide is a novel triple hormone receptor agonist under investigation for its effects on metabolic regulation. It is designed to simultaneously activate three receptors involved in energy and glucose homeostasis:
GLP-1 receptor (glucagon-like peptide-1)
GIP receptor (glucose-dependent insulinotropic polypeptide)
Glucagon receptor
By engaging all three pathways, retatrutide differs from single- or dual-agonist compounds (such as semaglutide or tirzepatide), which target only one or two of these receptors. This triple-agonist mechanism is of interest to researchers studying appetite regulation, insulin sensitivity, lipid metabolism, and energy expenditure.
Research applications include:
Obesity and body composition studies
Type 2 diabetes and glycemic control research
Investigations into hepatic fat reduction (e.g., NAFLD/MASLD models)
Comparative studies against GLP-1/GIP dual agonists
Molecular characteristics:
Peptide-based, developed by Eli Lilly
Currently in Phase 3 clinical trials (not yet FDA-approved)
Typically supplied as a lyophilized powder for reconstitution in research settings
Important: This product is intended strictly for in-vitro laboratory research use only. It is not for human or animal consumption, and is not a drug, food, or cosmetic. Not evaluated for safety, efficacy, or purity for clinical use. Handle only in a controlled research environment by qualified personnel.
Retatrutide is a novel triple hormone receptor agonist under investigation for its effects on metabolic regulation. It is designed to simultaneously activate three receptors involved in energy and glucose homeostasis:
GLP-1 receptor (glucagon-like peptide-1)
GIP receptor (glucose-dependent insulinotropic polypeptide)
Glucagon receptor
By engaging all three pathways, retatrutide differs from single- or dual-agonist compounds (such as semaglutide or tirzepatide), which target only one or two of these receptors. This triple-agonist mechanism is of interest to researchers studying appetite regulation, insulin sensitivity, lipid metabolism, and energy expenditure.
Research applications include:
Obesity and body composition studies
Type 2 diabetes and glycemic control research
Investigations into hepatic fat reduction (e.g., NAFLD/MASLD models)
Comparative studies against GLP-1/GIP dual agonists
Molecular characteristics:
Peptide-based, developed by Eli Lilly
Currently in Phase 3 clinical trials (not yet FDA-approved)
Typically supplied as a lyophilized powder for reconstitution in research settings
Important: This product is intended strictly for in-vitro laboratory research use only. It is not for human or animal consumption, and is not a drug, food, or cosmetic. Not evaluated for safety, efficacy, or purity for clinical use. Handle only in a controlled research environment by qualified personnel.